Ticker

CeriBell (NASDAQ: CBLL - Get Free Report) and Nephros (NASDAQ: NEPH - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings. Insider and Institutional Ownership 41.1% of Nephros shares are

CeriBell, Inc. (CBLL) Q4 2025 Earnings Call Transcript

CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.4 per share a year ago.

SUNNYVALE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025.

SUNNYVALE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the company will be participating in two upcoming investor conferences. Scott Blumberg, CFO, will present at the upcoming Raymond James 47th Annual Institutional Investors…